Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Moxifloxacin in multidrug-resistant tuberculosis: is there any indication for therapeutic drug monitoring?

Katerina Manika, Kalliopi Chatzika, Konstantinos Zarogoulidis, Ioannis Kioumis
European Respiratory Journal 2012 40: 1051-1053; DOI: 10.1183/09031936.00202411
Katerina Manika
*Pulmonary Dept, Aristotle University of Thessaloniki, “G. Papanikolaou” Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kalliopi Chatzika
#Clinical Pharmacokinetics Laboratory, Respiratory Infections Unit, Pulmonary Dept, Aristotle University of Thessaloniki, “G. Papanikolaou” Hospital, Thessaloniki, Greece
#Clinical Pharmacokinetics Laboratory, Respiratory Infections Unit, Pulmonary Dept, Aristotle University of Thessaloniki, “G. Papanikolaou” Hospital, Thessaloniki, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Konstantinos Zarogoulidis
*Pulmonary Dept, Aristotle University of Thessaloniki, “G. Papanikolaou” Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ioannis Kioumis
*Pulmonary Dept, Aristotle University of Thessaloniki, “G. Papanikolaou” Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ikioum@yahoo.gr
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

To the Editors:

Fluoroquinolones are rapidly emerging as important drugs in the treatment of tuberculosis (TB) worldwide [1]. In drug-susceptible TB, their use is currently under investigation and, according to the American Thoracic Society/Centers for Disease Control guidelines, fluoroquinolones are indicated only in patients receiving the conventional regimen who present severe adverse reactions [2]. However, in drug-resistant (DR) and, more specifically, in multidrug-resistant (MDR)-TB, the role of fluoroquinolones is much better established. Later-generation fluoroquinolones are included even in extensively drug resistant (XDR)-TB regimens since they may have some efficacy against ofloxacin-resistant strains [3].

The area under the concentration–time curve up to 24 h post-dosage (AUC24) is generally considered as the best predictor of fluoroquinolone efficacy [1]. Among fluoroquinolones, moxifloxacin is considered the most bactericidal, with potency comparable to that of isoniazid, and also seems to have some sterilising activity [1]. The maximal concentration (Cmax) of moxifloxacin exceeds mutant prevention concentration [1] and the currently recommended dose of 400 mg is likely to suppress the emergence of resistance in 60% of patients [4]. However, pharmacokinetic data on moxifloxacin in patients with TB are scarce, especially in the setting of an MDR-TB regimen.

In this report of a pilot prospective study, we present preliminary data on pharmacokinetic parameters in patients with MDR- or XDR-TB receiving second-line treatment. Patients were receiving moxifloxacin (Avelox®; Bayer, Leverkusen, Germany) p.o. for ≥4 days, in order to achieve a steady state, as part of their anti-TB treatment, which was based on drug susceptibility test results. Quinolone resistance was determined by ofloxacin susceptibility testing. All patients gave informed written consent and the study was approved by the hospital’s ethical committee.

Plasma samples were collected via a peripheral venous catheter immediately before and 1, 1.5, 2, 3, 4, 6, 9, 12 and 24 h after the moxifloxacin dose. Samples were stored at -20°C until they were analysed. Moxifloxacin concentration was determined by high-performance liquid chromatography with fluorescence detection as previously described [5]. The AUC24 was calculated according to the trapezoidal rule.

Seven patients (five males and two females, mean±sdage 40.1±15.7 yrs) were included in the study. All patients were HIV negative, suffered from extensive pulmonary TB, and had normal renal and hepatic function. Patients received 400 mg of moxifloxacin daily, a mean dose of 5.5 mg·kg−1. None of the patients was on treatment with antacids, sucralfate, drugs containing metal cations, multivitamins containing iron or zinc, nonsteroidal anti-inflammatory drugs, or class IA and III antiarrhythmics. Moxifloxacin was well tolerated and no adverse effects were reported. The mean period of treatment until sample collection was 244.1±257.3 days. Patients’ characteristics, comorbidities, anti-TB drugs, pharmacokinetic parameters and outcomes are presented in table 1. Mean Cmax was 4.59±2.06 mg·L−1 and was reached after 2.36±0.56 h (Tmax). Mean AUC24 was 37.96±16.52 mg·h·L−1. Both Cmax and AUC24 showed a high variability.

View this table:
  • View inline
  • View popup
Table 1– Patients’ characteristics, comorbidities, medication, pharmacokinetic parameters and outcomes

To our knowledge, this is the first pharmacokinetic analysis of moxifloxacin in a series of patients with MDR-TB. Concerning Cmax and AUC24, our results are in agreement with previous reports on moxifloxacin pharmacokinetics in healthy volunteers [6]. In addition, Peloquin et al. [7] and Nijiland et al. [8], in two interesting studies administered moxifloxacin in patients with drug-susceptible TB either before or after the end of standard treatment, observed similar results. However, in the only study evaluating pharmacokinetic parameters in the setting of an anti-TB regimen, significantly lower values were detected (Cmax 2.5 mg·L−1, AUC24 24.8 mg·h·L−1) [9]. The reasons for this discrepancy are not clear. One possible explanation might be the co-administration of rifampicin in 10 out of 16 patients for whom pharmacokinetic analysis was available, although the moxifloxacin AUC24 was not statistically significantly different between patients who received rifampicin and those who did not [9]. As shown by Nijland et al. [8], rifampicin reduces moxifloxacin Cmax and AUC24 by ∼30%. The percentage of 30% corresponds to the difference between our results and those of Pranger et al. [9]. Rifampicin, like all absorbable rifamycins, is a well-known inducer of cytochrome P450 isoenzymes, and induces phase II metabolic processes of glucuronidation and sulfation. Since cytochrome P450 is not involved in moxifloxacin metabolism, the rifampicin–moxifloxacin interaction is expected to result from the induction of phase II metabolism. It is noteworthy that three of our patients were receiving rifabutin. To our knowledge, no trials examining the effect of rifabutin on moxifloxacin metabolism have been conducted. However, the possibility of an interaction between these two drugs cannot be excluded, although, according to our results, it would probably be weaker than the rifampicin–moxifloxacin interaction. It is known that rifabutin is a less potent enzyme inducer than rifampicin. Isoniazid, which was also administered in the study by Nijiland et al. [8], is only known to affect cytochrome P450 metabolism and, thus, it is not expected to alter moxifloxacin levels. Therefore, considering moxifloxacin levels, patients with MDR-TB receiving moxifloxacin (but not rifampicin) have an advantage in comparison with patients with DR-TB receiving both drugs. Interactions between moxifloxacin and pyrazinamide or second-line agents have not been clearly established in the literature.

In contradiction to previous data, in the present study, mean Tmax was more than double the value usually observed. This discrepancy may be attributed to co-administered drugs the impact of which on the pharmacokinetics of moxifloxacin has not been investigated yet. Interestingly, Tmax reached its higher value (3 h) in the two patients with the lowest Cmax and AUC24.

In accordance with the study by Pranger et al. [9], a high variability of Cmax and AUC24 values was observed. As shown in table 1, two groups of patients can be recognized, those with a Cmax of ∼6 mg·L−1 and an AUC24>50 mg·h·L−1, and those with significantly lower values. In the first group, the AUC24/minimum inhibitory concentration (MIC) ratio would exceed 100 for an MIC of 0.5 mg·L−1. These differences are hard to explain since patients were repeatedly instructed not to use medications with known effects on moxifloxacin metabolism. Additionally, none of the patients was underweight at the time of the pharmacokinetic analysis or during the whole anti-TB treatment, with the exception of patient 7, a patient with cystic fibrosis. In the case of patient 5, low values may be explained by poor compliance. The case of patient 4 with ofloxacin-resistant TB is more intriguing, since there were no compliance issues and low AUC24 may actually have deprived this patient of a possible cure. Surprisingly, the clinical condition of this patient remained exceptionally good despite treatment failure. However, given the complexity of the second-line regimens, it is difficult to attribute this treatment failure strictly to the low levels of moxifloxacin. It has been suggested that moxifloxacin may be effective in ofloxacin-resistant TB when MIC is ≤2 mg·L−1 [10]. Therefore, in agreement with Pranger et al. [9], we conclude that the standard dose of 400 mg of moxifloxacin is not sufficient for all patients and this is especially true for XDR-TB cases.

In this setting, monitoring of therapeutic concentrations of moxifloxacin, particularly in patients with XDR-TB, could have a significant impact on clinical decisions. However, it is noteworthy that the pharmacodynamic target for Mycobacterium tuberculosis has not been defined, i.e. it is not clear whether the AUC24/MIC ratio should exceed 40 (as in the case of Gram-positive bacteria) or 100 (as is generally indicated in the case of Gram-negative bacterial infections). Given the complexity of anti-TB regimens and the variability of moxifloxacin concentrations among patients receiving the same regimen, it is imperative that specific pharmacodynamic targets should be determined through properly designed clinical trials and, hence, appropriate adjustments of dosage may be attempted in clinical practice.

Footnotes

  • Statement of Interest

    None declared.

  • ©ERS 2012

REFERENCES

  1. ↵
    1. Ginsburg AS,
    2. Grosset JH,
    3. Bishai WR
    . Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003; 3: 432–442.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603–662.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Falzon D,
    2. Jaramillo E,
    3. Schünemann HJ,
    4. et al
    . WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516–528.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Gumbo T,
    2. Louie A,
    3. Deziel MR,
    4. et al
    . Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004; 190: 1642–1651.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Liang H,
    2. Kays MB,
    3. Sowinski KM
    . Separation of levofloxacin, gatifloxacin, moxifloxacin, trovafloxacin and cinoxacin by HPLC: application to levofloxacin determination in human plasma. J Chromatogr B Analyt Technol Life Sci 2002; 772: 53–63.
    OpenUrlCrossRef
  6. ↵
    1. Nightingale CH
    . Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. Pharmacotherapy 2000; 20: 245–256.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Peloquin CA,
    2. Hadad DJ,
    3. Molino LP,
    4. et al
    . Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52: 852–857.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Nijland HM,
    2. Ruslami R,
    3. Suroto AJ,
    4. et al
    . Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis 2007; 45: 1001–1007.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Pranger AD,
    2. van Altena R,
    3. Aarnoutse RE,
    4. et al
    . Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J 2011; 38: 888–894.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Poissy J,
    2. Aubry A,
    3. Fernandez C,
    4. et al
    . Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother 2010; 54: 4765–4771.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 40 Issue 4 Table of Contents
European Respiratory Journal: 40 (4)
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Moxifloxacin in multidrug-resistant tuberculosis: is there any indication for therapeutic drug monitoring?
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Moxifloxacin in multidrug-resistant tuberculosis: is there any indication for therapeutic drug monitoring?
Katerina Manika, Kalliopi Chatzika, Konstantinos Zarogoulidis, Ioannis Kioumis
European Respiratory Journal Oct 2012, 40 (4) 1051-1053; DOI: 10.1183/09031936.00202411

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Moxifloxacin in multidrug-resistant tuberculosis: is there any indication for therapeutic drug monitoring?
Katerina Manika, Kalliopi Chatzika, Konstantinos Zarogoulidis, Ioannis Kioumis
European Respiratory Journal Oct 2012, 40 (4) 1051-1053; DOI: 10.1183/09031936.00202411
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Predictors of treatment outcome in MDR-TB in Portugal
  • Drug concentration in lung tissue in MDR-TB
  • Obesity in COPD: the effect of water-based exercise
Show more Letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society